Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thalys operates a broad portfolio of diagnostic platforms for chronic disease management, cancer screening/monitoring (including CTC detection), endocrine/metabolic diagnostics, infectious disease testing including sepsis pathogen ID/drug sensitivity testing. The company provides both in-hospital and out-of-hospital diagnostic solutions with a focus on digital transformation and integration of advanced technologies such as AI and big data to enable lean hospital management and smart healthcare ecosystems. It has established dual headquarters in Wuhan and Shanghai since its expansion in recent years.
No clinical trial results are reported as the company focuses on diagnostics/services rather than therapeutics.
The company’s independent third-party laboratory "THALYS MEDLAB" was established in May 2021.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Thalys Medical Technology.